<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombohemorrhagic balance is maintained by complicated interactions between the coagulation and fibrinolytic system, platelets, and the vessel wall </plain></SENT>
<SENT sid="1" pm="."><plain>Dr. Virchow provided approach for investigating and managing thrombotic disorders </plain></SENT>
<SENT sid="2" pm="."><plain>He proposed stasis, vascular injury, and <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> as causes for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In 1965, <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> was described </plain></SENT>
<SENT sid="4" pm="."><plain>After two decades, protein C and <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiencies</z:e>, mutations of factor V Leiden, and factor II were described </plain></SENT>
<SENT sid="5" pm="."><plain>If we distinguish patients at high risk and low risk of <z:mp ids='MP_0005048'>thrombosis</z:mp>, we can optimize therapeutic decisions </plain></SENT>
<SENT sid="6" pm="."><plain>There is currently no evidence to say that <z:hpo ids='HP_0001939'>laboratory abnormality</z:hpo> should influence intensity of anticoagulation </plain></SENT>
<SENT sid="7" pm="."><plain>In this article we reviewed the risk factors and need for <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> screening in patients </plain></SENT>
<SENT sid="8" pm="."><plain>Screening general population for <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> is not justified or recommended at this time </plain></SENT>
</text></document>